Measured Risk Portfolios’s Moderna MRNA Stock Holding History

Measured Risk Portfolios’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-117	Closed	-$4.87K	–	218
2024 Q4	$4.87K	Buy	+117	New	+$5.59K	0.01%	215

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Measured Risk Portfolios's MRNA Position: Q1 2025 in Review

Measured Risk Portfolios sold out of Moderna (MRNA) in Q1 2025, closing a stake of 117 shares — an estimated $4.87K sold.

Measured Risk Portfolios first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $4.87K in Q4 2024. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

Measured Risk Portfolios reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
Measured Risk Portfolios sold 117 Moderna shares in Q1 2025, an estimated $4.87K.
Measured Risk Portfolios first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
Measured Risk Portfolios's Moderna position peaked at $4.87K in Q4 2024.
693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Measured Risk Portfolios's 13F filing for Q1 2025, filed 13 May 2025.